Monday, November 12, 2012
Biotron Ltd., of Sydney, Australia, started a Phase II trial with its lead antiviral drug candidate, BIT225 in patients that are co-infected with both HIV and hepatitis C virus (HCV).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.